Following a story · 2 updates
Tempus AI to acquire Personalis for about $1.9 billion
Jul 21, 2026 – Jul 26, 2026
-
Tempus AI to acquire cancer-testing company Personalis for approximately $1.5 billion
Tempus AI agreed to pay $16.25 per share, approximately $1.5 billion net enterprise value, for Personalis and its minimal residual disease cancer-recurrence blood test, with the deal expected to close in late 2026 or early 2027 pending regulatory and shareholder approval.
Read this issue → -
Tempus AI to acquire Personalis for about $1.9 billion
Tempus AI agreed to pay $16.25 per share for Personalis in a deal structured as all-stock with an option to pay up to 50 percent in cash, expanding its molecular residual disease cancer-testing platform.
Read this issue →